Concizumab vs Fitusiran Hemophilia A Race — PatSnap Eureka
Concizumab in Hemophilia A with Inhibitors: Novo Nordisk vs. the Anti-TFPI & RNAi Race
Concizumab, Novo Nordisk's once-monthly anti-TFPI monoclonal antibody, is advancing through Phase III trials as fitusiran and marstacimab mount competing challenges in the non-factor subcutaneous prophylaxis space for hemophilia A and B with inhibitors.
Pipeline Agent Profile: Key Differentiators
Concizumab vs. fitusiran across five strategic dimensions derived from clinical and patent data.
How Concizumab Rebalances Hemostasis via TFPI Inhibition
Concizumab is a humanised monoclonal antibody that binds and inhibits Tissue Factor Pathway Inhibitor (TFPI), a natural anticoagulant that dampens the extrinsic coagulation pathway. In patients with hemophilia A who have developed inhibitors against factor VIII, standard replacement therapy is ineffective. By blocking TFPI, concizumab restores thrombin generation through the extrinsic pathway — independent of factor VIII — providing prophylactic bleed protection via once-monthly subcutaneous injection.
This rebalancing-of-hemostasis approach places concizumab in the same strategic class as fitusiran and marstacimab. Fitusiran, developed by Sanofi, takes a distinct molecular route: it uses RNA interference (RNAi) to reduce antithrombin levels, shifting the coagulation equilibrium toward clot formation. Marstacimab, developed by Pfizer, shares concizumab's anti-TFPI target but is a fully human antibody evaluated in the BASIS Phase III trial. Both fitusiran and marstacimab therefore represent direct competitive threats — one mechanistically parallel, one mechanistically identical.
The approved benchmark in this space is emicizumab (Hemlibra, Roche/Chugai), a bispecific antibody that mimics factor VIII cofactor function. Emicizumab is approved for hemophilia A with and without inhibitors and has set a high bar for subcutaneous prophylaxis. Concizumab must demonstrate competitive annualised bleeding rate (ABR) reduction, a favourable safety profile — particularly regarding thrombotic risk — and the potential advantage of covering both hemophilia A and hemophilia B with inhibitors.
The patent landscape around anti-TFPI antibodies reveals intensive filing activity from Novo Nordisk, with key composition-of-matter patents covering the concizumab antibody sequence and its TFPI epitope. Understanding freedom-to-operate and expiry timelines is critical for lifecycle management as the Phase III readout approaches.
Four Non-Factor Agents Reshaping Hemophilia A Inhibitor Prophylaxis
Each agent targets a distinct node in the coagulation cascade, but all compete for the same patient population currently managed with intravenous bypassing agents.
Concizumab — explorer7 Phase III
Humanised monoclonal antibody targeting TFPI. Administered as a once-monthly subcutaneous injection. The explorer7 trial evaluates prophylaxis in hemophilia A and B patients with inhibitors, while explorer8 targets the non-inhibitor population. Concizumab's coverage of both hemophilia A and B with inhibitors distinguishes it from emicizumab, which is approved only for hemophilia A.
Phase III · Monthly SC · HemA+B inhibitorsFitusiran — ATLAS Phase III
Small interfering RNA therapeutic that silences antithrombin synthesis in the liver, reducing antithrombin levels to promote thrombin generation. Once-monthly subcutaneous dosing. The ATLAS programme covers hemophilia A and B with and without inhibitors. A clinical hold was previously placed following a thrombotic event, leading to dose modifications that now define the approved dosing regimen.
Phase III · Monthly SC · HemA+B ± inhibitorsMarstacimab — BASIS Phase III
Fully human monoclonal antibody targeting TFPI — the same molecular target as concizumab. Evaluated in the BASIS Phase III trial for severe hemophilia A or B with or without inhibitors. Once-weekly subcutaneous dosing differentiates its administration schedule from concizumab's monthly regimen, potentially offering a different pharmacodynamic profile at the cost of injection frequency.
Phase III · Weekly SC · HemA+B ± inhibitorsEmicizumab (Hemlibra) — Approved Benchmark
Bispecific antibody bridging activated factor IX and factor X to mimic factor VIII cofactor function. Approved for hemophilia A with and without inhibitors. Available in weekly, biweekly, and monthly subcutaneous dosing options. Emicizumab is the current standard of care and the commercial benchmark against which concizumab, fitusiran, and marstacimab must demonstrate differentiation in clinical and real-world outcomes.
Approved · Weekly/biweekly/monthly SC · HemA onlyMechanism, Dosing & Coverage: Concizumab vs. the Field
Visualising the key differentiators across the four non-factor subcutaneous prophylaxis agents competing in hemophilia A with inhibitors.
Subcutaneous Injection Frequency (doses/month)
Concizumab and fitusiran share the lowest injection burden at once monthly; marstacimab requires four injections per month.
Patient Population Coverage: Inhibitor vs. Non-Inhibitor
Concizumab's explorer programme covers both inhibitor (explorer7) and non-inhibitor (explorer8) populations across hemophilia A and B.
Concizumab vs. Fitusiran vs. Marstacimab: Key Attributes
A structured comparison of the three Phase III non-factor agents competing in the hemophilia inhibitor prophylaxis space.
| Attribute | Concizumab | Fitusiran | Marstacimab |
|---|---|---|---|
| Developer | Novo Nordisk | Sanofi | Pfizer |
| Modality | Humanised anti-TFPI mAb | Anti-antithrombin RNAi (siRNA) | Fully human anti-TFPI mAb |
| Target | TFPI (Kunitz domain 2) | Antithrombin (SERPINC1) | TFPI (Kunitz domain 2) |
| Dosing | Once monthly SC | Once monthly SC | Once weekly SC |
| Phase III Trial | explorer7 (inhibitors), explorer8 (non-inhibitors) | ATLAS-INH, ATLAS-A/B, ATLAS-PPX | BASIS |
| Hemophilia Coverage | A and B (with inhibitors) | A and B (with and without inhibitors) | A and B (with and without inhibitors) |
| Key Safety Signal | Thrombotic events (dose-dependent monitoring) | Thrombotic events (prior clinical hold; dose modified) | Thrombotic events (anti-TFPI class effect) |
Need deeper competitive intelligence on the hemophilia pipeline?
PatSnap Eureka combines patent data, clinical trial filings, and literature in one AI-powered search.
What the Patent Landscape Reveals About the Anti-TFPI Race
Key strategic signals from patent filings and clinical development timelines for hemophilia A non-factor prophylaxis.
Shared TFPI Target Creates FTO Complexity
Both concizumab and marstacimab target the Kunitz domain 2 of TFPI. The overlap in molecular target creates a complex freedom-to-operate environment, where composition-of-matter patents for each antibody's specific sequence are distinct, but method-of-use claims may overlap. Monitoring patent prosecution and inter partes review activity at the USPTO and EPO is essential for lifecycle planning.
Monthly Dosing as the New Prophylaxis Standard
Concizumab and fitusiran both achieve once-monthly subcutaneous dosing, matching the most convenient emicizumab schedule. Marstacimab's once-weekly requirement positions it at a disadvantage for patient convenience, but may offer more stable pharmacodynamic coverage. The dosing frequency patent claims — covering formulation and delivery device — are a secondary battleground in this pipeline race.
Key Development Signals to Watch in the Hemophilia A Inhibitor Race
Critical milestones and status indicators for concizumab, fitusiran, and marstacimab from PatSnap Eureka intelligence.
Concizumab explorer7 Phase III — Inhibitor Cohort Enrolment
The explorer7 trial is actively enrolling patients with hemophilia A or B and inhibitors for once-monthly subcutaneous concizumab prophylaxis. Primary endpoint is annualised bleeding rate reduction versus no prophylaxis.
Fitusiran ATLAS Programme — Post-Hold Dosing Confirmed
Following the clinical hold and dose modification, the ATLAS Phase III programme for fitusiran has resumed with revised dosing protocols. Monthly subcutaneous antithrombin-targeting RNAi prophylaxis continues across the inhibitor and non-inhibitor cohorts.
Marstacimab BASIS Trial — Weekly Dosing Differentiation Analysis
The BASIS Phase III trial for marstacimab (Pfizer) evaluates once-weekly subcutaneous anti-TFPI prophylaxis in severe hemophilia A and B. The weekly dosing schedule versus concizumab's monthly regimen is a key comparative endpoint for commercial positioning.
Thrombotic Risk Class Effect — Regulatory Guidance Pending
All three rebalancing agents (concizumab, fitusiran, marstacimab) carry a class-level thrombotic risk signal. Regulatory agencies including the EMA and FDA are expected to issue guidance on risk mitigation strategies and labelling requirements applicable across the anti-TFPI and anti-AT therapeutic class.
Set automated alerts for concizumab trial milestones
Patent publications, clinical trial updates, and regulatory filings — all in one PatSnap intelligence feed.
Concizumab & Hemophilia A Inhibitor Pipeline — key questions answered
Concizumab is a monoclonal antibody developed by Novo Nordisk that targets Tissue Factor Pathway Inhibitor (TFPI). By inhibiting TFPI, concizumab restores thrombin generation through the extrinsic coagulation pathway, providing prophylactic bleed protection for patients with hemophilia A or B who have developed inhibitors against standard factor replacement therapies. It is administered as a once-monthly subcutaneous injection.
Concizumab is being evaluated in the Phase III explorer7 and explorer8 clinical trial programme. explorer7 focuses on patients with hemophilia A or B with inhibitors, while explorer8 targets patients without inhibitors. These trials assess once-monthly subcutaneous concizumab as prophylaxis to prevent bleeding episodes.
Fitusiran is an RNA interference (RNAi) therapeutic developed by Sanofi that targets antithrombin, reducing its levels to shift the coagulation balance toward clot formation. In contrast, concizumab targets TFPI, a different inhibitor of the coagulation cascade. Both approaches aim to rebalance hemostasis without requiring factor replacement, but they act on distinct molecular targets and use different modality platforms — small interfering RNA versus monoclonal antibody.
Marstacimab is a fully human monoclonal antibody developed by Pfizer that also targets TFPI, sharing the same mechanism of action as concizumab. It is being evaluated in the BASIS Phase III trial for patients with severe hemophilia A or B, with or without inhibitors. Marstacimab represents a direct mechanistic competitor to concizumab in the anti-TFPI subcutaneous prophylaxis space.
Patients with hemophilia A who develop inhibitors — neutralising antibodies against infused factor VIII — lose the ability to benefit from standard factor replacement therapy. Bypassing agents such as activated prothrombin complex concentrate (aPCC) and recombinant factor VIIa exist but require frequent intravenous dosing and provide inconsistent hemostatic coverage. Non-factor subcutaneous therapies like emicizumab, concizumab, fitusiran, and marstacimab offer more convenient dosing and do not rely on the factor VIII pathway, addressing this high unmet need directly.
Emicizumab (Hemlibra), developed by Roche/Chugai, is an approved bispecific antibody that mimics the cofactor function of factor VIII by bridging activated factor IX and factor X. It is already approved for hemophilia A with and without inhibitors and represents the current standard of care for subcutaneous prophylaxis. Concizumab, fitusiran, and marstacimab are all competing to offer differentiated profiles — including coverage of hemophilia B with inhibitors and potentially broader hemostasis rebalancing — versus the established emicizumab benchmark.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About Concizumab →Stay Ahead in the Hemophilia A Non-Factor Prophylaxis Race
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D and competitive intelligence workflows.
References
- National Institutes of Health (NIH) — Hemophilia A and Inhibitor Development
- Sanofi — Fitusiran (ATLAS Phase III Programme)
- Pfizer — Marstacimab (BASIS Phase III Trial)
- European Medicines Agency (EMA) — Haemostasis Rebalancing Therapeutic Class Guidance
- World Intellectual Property Organization (WIPO) — Anti-TFPI Antibody Patent Filings
- PatSnap Analytics — Hemophilia Pipeline Patent Landscape
- PatSnap Life Sciences Intelligence Platform
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform.
PatSnap Eureka searches patents and research to answer instantly.